ERBB2 and neoplasm: Considering the impact of different covariates in the current study, we found no associations between RGC32 promoter methylation and patients' age (P = 0.332), period age (P = 0.541), menopausal age (P = 0.197), tumor grade (P = 0.611), stage (P = 0.092), nodal metastasis (P = 0.245), estrogen receptor (P = 0.377), progesterone receptor (P = 0.489), and HER2 (P = 0.932).